Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
55.15
+1.38 (+2.57%)
Official Closing Price
Updated: 4:15 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
34
35
Next >
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
↗
November 28, 2023
These stocks may take off in a market favoring growth.
Via
The Motley Fool
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
↗
November 25, 2023
These innovators should have tremendous long-term growth prospects.
Via
The Motley Fool
Is CRISPR Therapeutics the Best Gene-Editing Stock?
↗
November 22, 2023
The biotech's first-mover advantage bodes well for its long-term prospects.
Via
The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
↗
November 22, 2023
Many biotech stocks offer exciting long-term growth prospects.
Via
The Motley Fool
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
↗
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
What's Going On With Crispr Therapeutics Stock Monday?
↗
November 20, 2023
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's
Via
Benzinga
Google’s Bard AI Says These 3 Stocks Will Rise 1,000%
↗
November 20, 2023
Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential.
Via
InvestorPlace
Topics
Artificial Intelligence
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
↗
November 20, 2023
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?
Via
The Motley Fool
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
↗
November 19, 2023
The stock is trading below its peak, reached a couple of years ago.
Via
The Motley Fool
3 Monster Stocks in the Making
↗
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
Why CRISPR Therapeutics Stock Is Jumping Again Today
↗
November 17, 2023
The stock continues to enjoy momentum from a key regulatory approval.
Via
The Motley Fool
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
↗
November 17, 2023
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.
Via
Benzinga
Topics
Stocks
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
↗
November 17, 2023
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
3 Long-Term Growth Stocks Analysts Are Bullish On
↗
November 16, 2023
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two.
Via
InvestorPlace
3 Cathie Wood You’ll Regret Not Buying Soon: November 2023
↗
November 16, 2023
Cathie Wood thinks we're out of the woods economically, and these stock picks in her portfolio stand to gain the most in coming months.
Via
InvestorPlace
Why Is NIO Stock Down 5% Today?
↗
November 16, 2023
Nio stock is falling on Thursday as investors react to negative news following the summit between Presidents Xi Jinping and Joe Biden.
Via
InvestorPlace
Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug
↗
November 16, 2023
The drug will sell under the brand name Casgevy in the UK for two blood diseases.
Via
Investor's Business Daily
What's Going On With Crispr Therapeutics Stock Thursday?
↗
November 16, 2023
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene-
Via
Benzinga
Citi Is Souring on Plug Power (PLUG) Stock
↗
November 16, 2023
Plug Power stock is falling on Thursday after the EV charging company's shares were hit with a downgrade and lowered price target from Citi.
Via
InvestorPlace
CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy
↗
November 16, 2023
CRSP stock is up on U.K. authorization for its gene therapy treatment for sickle cell anemia. CRISPR hopes for FDA authorization next spring.
Via
InvestorPlace
UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia
↗
November 16, 2023
The U.K.
Via
Benzinga
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
↗
November 16, 2023
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results.
Via
Benzinga
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.
↗
November 16, 2023
A few things put together could push the stock higher.
Via
The Motley Fool
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Invest in the Future With These 7 Forever Stocks
↗
November 15, 2023
Forever stocks are usually those predicting future trends. Finding them today means pinning down strong financials and prospects without FOMO.
Via
InvestorPlace
3 Biotech Stocks With Key Catalysts Coming in December
↗
November 15, 2023
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.
Via
InvestorPlace
2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher
↗
November 14, 2023
These stocks look reasonably priced today considering their long-term prospects.
Via
The Motley Fool
Topics
Stocks
What's Going On With CRISPR Therapeutics Stock?
↗
November 13, 2023
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target. What To Know:
Via
Benzinga
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
↗
November 12, 2023
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.
Via
InvestorPlace
1 No-Brainer Stock to Buy and Hold for 10 Years
↗
November 11, 2023
This company has been in the news for much of the year.
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.